精神病基因组学中以家庭为基础的研究:2024 年的进展与意义

IF 6.1 2区 医学 Q1 CLINICAL NEUROLOGY European Neuropsychopharmacology Pub Date : 2024-10-01 DOI:10.1016/j.euroneuro.2024.08.079
Aiden Corvin (Chair) , Andrew McIntosh (Co-chair) , Niamh Ryan (Discussant)
{"title":"精神病基因组学中以家庭为基础的研究:2024 年的进展与意义","authors":"Aiden Corvin (Chair) ,&nbsp;Andrew McIntosh (Co-chair) ,&nbsp;Niamh Ryan (Discussant)","doi":"10.1016/j.euroneuro.2024.08.079","DOIUrl":null,"url":null,"abstract":"<div><div>To our knowledge it is ten years since the last symposium on pedigree-based analyses at the WCPG. In the era of whole genome sequencing a review is timely. As costs fall, the field of psychiatric genomics is transitioning from GWAS to next generation sequencing, with power to expand our understanding of the contribution of rare mutations to genetic burden across disorders. Identified rare pathogenic variants may be more informative in understanding disease biology than the common variants of small effect that represent the majority of discovery to date.</div><div>Rare variant association studies require sample sizes an order of magnitude larger than GWAS studies. This is because rare mutations tend to be selected against in populations over a few generations. However, such mutations may be identifiable where multiple generations of the same family are available. Moreover, families do not suffer the same population stratification or other confounds that are present at a population level. This approach, with small sample numbers in a family, allows for detailed phenotypic assessment and is accessible to clinicians and researchers with limited resources who want to contribute to the field.</div><div>This symposium will provide an update on progress made in ASD, where significant understanding of the genetic architecture and disease biology is emerging, in part due to trio- and quad-based approaches. We review progress from the PGC Pedigree Sequencing Group with an example of how sequencing individual families, with small numbers of individuals can identify relevant risk mutations only identifiable with thousands of samples using case-control approaches. We describe progress in other adult disorders from the international \"Pedigree-Based Whole Genome Sequencing of Affective and Psychotic Disorders\" consortium. Finally, we review the findings from colleagues working in India who are applying pedigree-based sequencing study approaches across disorders. Across presentations we consider recruitment, and how emerging findings indicate a need for broader inclusion criteria within families than might traditionally have been considered. This session will also present new methods for investigating pedigrees in the era of whole genome sequencing.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"87 ","pages":"Pages 31-32"},"PeriodicalIF":6.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"FAMILY-BASED STUDIES IN PSYCHIATRIC GENOMICS: PROGRESS AND RELEVANCE IN 2024\",\"authors\":\"Aiden Corvin (Chair) ,&nbsp;Andrew McIntosh (Co-chair) ,&nbsp;Niamh Ryan (Discussant)\",\"doi\":\"10.1016/j.euroneuro.2024.08.079\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>To our knowledge it is ten years since the last symposium on pedigree-based analyses at the WCPG. In the era of whole genome sequencing a review is timely. As costs fall, the field of psychiatric genomics is transitioning from GWAS to next generation sequencing, with power to expand our understanding of the contribution of rare mutations to genetic burden across disorders. Identified rare pathogenic variants may be more informative in understanding disease biology than the common variants of small effect that represent the majority of discovery to date.</div><div>Rare variant association studies require sample sizes an order of magnitude larger than GWAS studies. This is because rare mutations tend to be selected against in populations over a few generations. However, such mutations may be identifiable where multiple generations of the same family are available. Moreover, families do not suffer the same population stratification or other confounds that are present at a population level. This approach, with small sample numbers in a family, allows for detailed phenotypic assessment and is accessible to clinicians and researchers with limited resources who want to contribute to the field.</div><div>This symposium will provide an update on progress made in ASD, where significant understanding of the genetic architecture and disease biology is emerging, in part due to trio- and quad-based approaches. We review progress from the PGC Pedigree Sequencing Group with an example of how sequencing individual families, with small numbers of individuals can identify relevant risk mutations only identifiable with thousands of samples using case-control approaches. We describe progress in other adult disorders from the international \\\"Pedigree-Based Whole Genome Sequencing of Affective and Psychotic Disorders\\\" consortium. Finally, we review the findings from colleagues working in India who are applying pedigree-based sequencing study approaches across disorders. Across presentations we consider recruitment, and how emerging findings indicate a need for broader inclusion criteria within families than might traditionally have been considered. This session will also present new methods for investigating pedigrees in the era of whole genome sequencing.</div></div>\",\"PeriodicalId\":12049,\"journal\":{\"name\":\"European Neuropsychopharmacology\",\"volume\":\"87 \",\"pages\":\"Pages 31-32\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Neuropsychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0924977X24002785\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924977X24002785","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

据我们所知,距离上一次在世界基因组大会上举办基于谱系分析的研讨会已经过去了十年。在全基因组测序时代,进行一次回顾是非常及时的。随着成本的下降,精神疾病基因组学领域正在从全球基因组分析系统(GWAS)向新一代测序系统过渡,这将有助于我们进一步了解罕见变异对各种疾病遗传负担的影响。在了解疾病生物学方面,发现的罕见致病变异可能比迄今为止发现的大多数影响较小的常见变异更有参考价值。罕见变异关联研究需要的样本量要比 GWAS 研究大一个数量级。这是因为罕见变异在人群中往往会经过几代人的选择而被淘汰。然而,在同一家族有多代人的情况下,这种突变可能是可识别的。此外,家族也不会受到人群分层的影响,也不会受到人群水平上存在的其他干扰因素的影响。本研讨会将介绍 ASD 研究的最新进展,在 ASD 研究中,人们对遗传结构和疾病生物学有了更深入的了解,这部分归功于基于三代和四代的研究方法。我们将回顾 PGC Pedigree Sequencing Group 取得的进展,并举例说明对个体数量较少的单个家庭进行测序如何发现相关的风险突变,而只有使用病例对照方法对成千上万的样本进行测序才能发现这些突变。我们还介绍了国际 "情感和精神障碍基于谱系的全基因组测序 "联盟在其他成人疾病方面取得的进展。最后,我们回顾了在印度工作的同事的研究成果,他们将基于 pedigree 的测序研究方法应用于各种疾病。在所有发言中,我们都会考虑招募问题,以及新出现的研究结果如何表明需要比传统上考虑的更广泛的家庭纳入标准。本次会议还将介绍在全基因组测序时代调查家系的新方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
FAMILY-BASED STUDIES IN PSYCHIATRIC GENOMICS: PROGRESS AND RELEVANCE IN 2024
To our knowledge it is ten years since the last symposium on pedigree-based analyses at the WCPG. In the era of whole genome sequencing a review is timely. As costs fall, the field of psychiatric genomics is transitioning from GWAS to next generation sequencing, with power to expand our understanding of the contribution of rare mutations to genetic burden across disorders. Identified rare pathogenic variants may be more informative in understanding disease biology than the common variants of small effect that represent the majority of discovery to date.
Rare variant association studies require sample sizes an order of magnitude larger than GWAS studies. This is because rare mutations tend to be selected against in populations over a few generations. However, such mutations may be identifiable where multiple generations of the same family are available. Moreover, families do not suffer the same population stratification or other confounds that are present at a population level. This approach, with small sample numbers in a family, allows for detailed phenotypic assessment and is accessible to clinicians and researchers with limited resources who want to contribute to the field.
This symposium will provide an update on progress made in ASD, where significant understanding of the genetic architecture and disease biology is emerging, in part due to trio- and quad-based approaches. We review progress from the PGC Pedigree Sequencing Group with an example of how sequencing individual families, with small numbers of individuals can identify relevant risk mutations only identifiable with thousands of samples using case-control approaches. We describe progress in other adult disorders from the international "Pedigree-Based Whole Genome Sequencing of Affective and Psychotic Disorders" consortium. Finally, we review the findings from colleagues working in India who are applying pedigree-based sequencing study approaches across disorders. Across presentations we consider recruitment, and how emerging findings indicate a need for broader inclusion criteria within families than might traditionally have been considered. This session will also present new methods for investigating pedigrees in the era of whole genome sequencing.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
European Neuropsychopharmacology
European Neuropsychopharmacology 医学-精神病学
CiteScore
10.30
自引率
5.40%
发文量
730
审稿时长
41 days
期刊介绍: European Neuropsychopharmacology is the official publication of the European College of Neuropsychopharmacology (ECNP). In accordance with the mission of the College, the journal focuses on clinical and basic science contributions that advance our understanding of brain function and human behaviour and enable translation into improved treatments and enhanced public health impact in psychiatry. Recent years have been characterized by exciting advances in basic knowledge and available experimental techniques in neuroscience and genomics. However, clinical translation of these findings has not been as rapid. The journal aims to narrow this gap by promoting findings that are expected to have a major impact on both our understanding of the biological bases of mental disorders and the development and improvement of treatments, ideally paving the way for prevention and recovery.
期刊最新文献
Risk of mortality and complications in patients with severe mental illness and co-occurring diabetes mellitus: A systematic review and meta-analysis Editorial Board Corrigendum to “Lung function decline in people with serious mental illness: A call to action” [European Neuropsychopharmacology (2024) 41-46/ ENP-24-342] The need for specific mental health interventions for the prevention of suicide in postpandemic times Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1